News Releases

Date	Title and Summary	View
Dec 28, 2020	Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dec 21, 2020	Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Dec 21, 2020	Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe
Dec 18, 2020	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Dec 14, 2020	Johnson & Johnson to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Dec 11, 2020	Janssen Receives Positive CHMP Opinion for SPRAVATO®▼ (Esketamine Nasal Spray) for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder
Dec 07, 2020	New DARZALEX® (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma
Dec 07, 2020	Data from the ANDROMEDA Study Show Hematologic Response for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Newly Diagnosed Light Chain (AL) Amyloidosis
Dec 06, 2020	New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
Dec 05, 2020	Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma